Reading ANIP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANIP free→Reading ANIP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANIP free→NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been steady, while risk is moderate and the sector backdrop is a headwind. Peer multiples imply a price about 22% above where it trades (it looks cheap on this basis); the read is fair, quality intact. The company is not currently unprofitable, which supports the valuation. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $81.68. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $82 ANIP trades at 11× p/e, below its 13× p/e peer median. Our $101 fair value sits above the price; high confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 19% below a flat-multiple fair value, well above our forecast of about -60%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2.27x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $2.18 → $2.00 (-8.2% / 30d). 1 raised, 5 cut, 7 covering analysts.
0 upgrades, 0 downgrades / 30d. 88% of analysts rate Buy.
0 positive, 0 negative / 30d.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$123.
How much price usually moves either way.
On a bad day, this stock has moved -$276.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,866.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This will show if the company's growth strategy is working. A drop below 10% could signal trouble.
Confirms:Q2 revenue growth reported below 10% year over year.
Disproves:Q2 revenue growth reported at or above 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ANIP yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant ha…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ANIP ANI Pharmaceuticals, Inc. | Above typical Show detailsSector percentile: 70 of 100 | fair | moderate |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 85 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Typical Show detailsSector percentile: 69 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 62 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 62 of 100 | fair | low |
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on maximizing multi-year growth opportunities for Cortrophin Gel across various indications.
Continue to explore opportunities to expand the scope and scale of the Rare Disease business.
Maintain disciplined capital allocation with a focus on R&D and business development.
Continue to launch new Generics products, targeting 10-15 launches in 2026.
Initiate a $100 million share repurchase program authorized by the Board of Directors.
Why it matters: Cortrophin Gel growth is important for ANI's revenue and plans.
Confirms:Cortrophin Gel revenue for Q2 2026 exceeds $75 million, showing strong demand.
Disproves:Cortrophin Gel revenue for Q2 2026 is below $70 million. This shows weak demand.
Why it matters: New product launches can drive revenue growth and strengthen market position.
Confirms:ANI launches at least 3 new Generics products by the end of Q3 2026.
Disproves:ANI fails to launch any new Generics products by the end of Q3 2026.
Why it matters: Good results could help ILUVIEN make more money and reach more people.
Confirms one read:Good results were shown at a medical conference in Q3 2026 for the SYNCHRONICITY trial.
Confirms the other:Bad results or no news from the SYNCHRONICITY trial at the conference.
Why it matters: Cash flow is key for funding growth. Slowing growth could impact future investments.
Confirms:Cash from operations growth reported below 50% year over year in Q2.
Disproves:Cash from operations growth reported at or above 50% year over year in Q2.
Why it matters: News on the share repurchase program can show management's trust in the company.
Confirms:ANI announces completion of at least $25 million in share repurchases by Q4 2026.
Disproves:ANI provides no updates or fails to repurchase shares by Q4 2026.
The filing pertains to the approval of a stock incentive plan, not a management change.